Genenta Science SpA Sponsored ADR GNTA 深 沪
等待开盘 05-19 09:30:00 美东时间
0.6317
+0.004
+0.59%
华盛通- 最 高0.635
- 今 开0.61
- 成交量 3.52万股
- 最 低 0.60
- 昨 收 0.628
- 总市值 1.49万
- 52周最高 10.00
- 市盈率 静 --
- 换手率 0.15%
- 52周最低 0.55
- 委 比 57.48%
- 总股本 2.36万
- 历史最高 13.13
- 量 比 0.70
- 振 幅 5.57%
- 历史最低 0.55
- 每 手 1
- 风险率 1.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Genenta Science Signs Definitive Agreements With Sòphia High Tech; Genenta Expects To Fund Total Of €6 Million In Two Tranches
Genenta Science S.p.A. (NASDAQ:GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that it
04-23 19:13
Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini
<p>Genenta Science S.p.A. (Nasdaq: GNTA), renaming to Saentra Forge, focuses on strategic industrial consolidation in biotech, defense, aerospace, and cybersecurity. The company is exploring collaboration opportunities for its biotechnology platform, originated from research by founder-scientists, but has yet to identify strategic partners for Temferon or its platform. CEO Pierluigi Paracchi emphasizes no founder-scientist has sold shares and opp...
03-24 07:27
Genenta, Evolving into Saentra Forge, Announces CEO’s Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University
Genenta Science S.p.A. (更名为Saentra Forge) 宣布其CEO Pierluigi Paracchi被任命为意大利 Columbia 大学高级研究学院的担保人委员会成员。该学院致力于促进意大利与美国之间的文化与学术交流。Paracchi强调此任命将有助于深化意大利与美国在科学与文化领域的合作，推动意大利关键科技领域的发展。
03-13 09:00
Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform
Genenta Science S.p.A., transitioning to Saentra Forge, appoints Paolo Salvato to the Board of Directors of ATC, a defense technology manufacturer. The company is evaluating majority-control acquisition opportunities in national-security sectors. Salvato brings extensive experience in defense and aerospace. Nature Medicine has accepted a manuscript on clinical findings from its Glioblastoma trial, highlighting significant validation of its work. ...
02-27 09:00
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers ENvue Medical (NASDAQ:FEED) stock moved upwards by 19.0% to $1.25 duri...
01-28 20:05
Micro-Cap Genenta Stock Reacts To Its Big Pivot From Biotech To Defense Investments
Genenta plans a major shift into defense businesses, backing weapons maker ATC, rebranding as Saentra Forge and reshaping its future as shares see sharp moves.
01-28 01:45
Why Biomx Shares Are Trading Higher By Over 100%; Here Are 20 Stocks Moving Premarket
Shares of Biomx Inc (NYSE:PHGE) rose sharply in pre-market trading after a 13D ...
01-27 17:51
Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator
Genenta Science S.p.A. (Nasdaq: GNTA) is renaming itself as Saentra Forge S.p.A. and transitioning to focus on acquiring majority ownership in privately held Italian companies operating in national security sectors under the Golden Power framework. Its first acquisition is ATC, a high-precision manufacturer of tactical rifles and special-forces weapons. The company has also welcomed Praexidia Foundation as a long-term strategic shareholder to sup...
01-27 08:00
Genenta Science Provides Update on CEO Ownership
Genenta Science's CEO and Co-Founder, Pierluigi Paracchi, owns 2,326,129 ADSs and ordinary shares, representing approximately 10% of the company's outstanding share capital. Paracchi has acquired these shares through open-market purchases with no reported sales. The company, focused on gene therapy for solid tumors, is developing Temferon™, a hematopoietic stem cell therapy, with Phase 1 trials completed for GBM and Phase 1/2a initiated for metas...
2025-12-19 07:30
Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial
Genenta Science, a biotechnology company, reported updated results from its TEM-GBM study for newly diagnosed glioblastoma multiforme (GBM) patients with an unmethylated MGMT gene promoter. As of November 21, 2025, 25 patients treated with Temferon showed consistent survival metrics compared to April 2025 data: 44% reached 18-month survival, 29% achieved two-year survival, and median overall survival remained at 17 months. A patient reached three...
2025-11-24 09:00
